December 31, 2013
Read MoreDecember 10, 2013
CTI Clinical Trial and Consulting Services (CTI) announces David Facklam, MS has joined as Senior Director, Regulatory and Scientific Affairs. Mr. Facklam has over 30 years of experience in clinical drug development in the pharmaceutical industry. Prior to joining CTI, Mr. Facklam held positions of increasing responsibility in the ...
Read MoreDecember 7, 2013
The meeting is taking place in New Orleans, LA. If you will be attending, please contact us to schedule a meeting!
Read MoreNovember 20, 2013
CTI Clinical Trial and Consulting Services (CTI) announces William Aronstein, PhD, MD, FACP has been promoted to Vice President, Medical Affairs. Dr. Aronstein has vast experience in early phase clinical development, including protocol development, execution, and analysis, as well as over 30 years of clinical, academic, and industry experience. ...
Read MoreOctober 30, 2013
CTI Clinical Trial and Consulting Services (CTI) announces Timothy J. Schroeder, Chief Executive Officer, will participate in the 6th Annual Blue Ash Life Sciences Collaborative, taking place October 31, 2013 in Blue Ash, Ohio. CTI is also a proud sponsor of the event. Mr. Schroeder will moderate the Industry ...
Read MoreOctober 21, 2013
CTI Clinical Trial and Consulting Services (CTI)’s newly expanded department, S2 Health Economics Outcomes Research (S2 HECOR), announces the launch of S2 Hospital Insights, an innovative web-based tool that provides a look at definitive hospital reimbursement data. With this exclusive information, pharmaceutical, biotechnology, and medical device companies, along with healthcare ...
Read MoreOctober 11, 2013
CTI Clinical Trial and Consulting Services (CTI) announces Timothy J. Schroeder, Chief Executive Officer, will participate in a panel discussion at the 2013 Stem Cell Meeting on the Mesa, taking place October 14-16, 2013 in La Jolla, California. The meeting brings together members of the scientific research community and those ...
Read MoreSeptember 25, 2013
CTI Clinical Trial and Consulting Services (CTI) announces Timothy J. Schroeder, Chief Executive Officer, will present at the 2013 Studies in Pediatric Liver Transplantation (SPLIT) Annual Meeting, taking place September 26-27, 2013 in Toronto. Mr. Schroeder will present on the topic “The Challenges of Designing and Implementing Clinical Trials: ...
Read MoreSeptember 16, 2013
CTI Clinical Trial and Consulting Services (CTI) announces the hiring of Edward A. Kouche III, CPA as Director, International Accounting and Finance.Ed comes to CTI from INC Research (formerly Kendle International), where he worked for nearly 15 years. Throughout his time there, he served as International Controller, Corporate Controller, and ...
Read MoreSeptember 9, 2013
CTI Clinical Trial and Consulting Services (CTI) announces that it has opened an office in Milan, Italy. The office is opened through its newly created wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Italy, S.R.L. “We believe that the market for clinical research is continuing its growth throughout Europe, ...
Read MoreAugust 30, 2013
CTI Clinical Trial and Consulting Services (CTI) announces that Maria Marsh, Chief Financial Officer and Vice President at CTI, was named the Cincinnati Business Courier’s 2013 CFO of the Year. Maria was honored, along with the 21 other finalists of various Greater Cincinnati organizations, at the award ceremony on Thursday, ...
Read MoreAugust 28, 2013
CTI Clinical Trial and Consulting Services (CTI) was awarded the 2013 Goering Center Private Business Award. CTI was presented the award at the 14th annual ceremony, which took place August 27, 2013.The Goering Center recognized finalists and category winners for their success in family and private business. An independent panel ...
Read MoreAugust 13, 2013
Prior to joining CTI, Dr. Campaneria was with Inhibitex, a biopharmaceutical company, where he served as Medical Director, and led the development of several Hepatitis C programs. Dr. Campaneria also spent nearly ten years in multiple roles at Monitoring Force, an international Clinical Research Organization (CRO), conducting Phase II, III, ...
Read MoreAugust 7, 2013
CTI Clinical Trial and Consulting Services announces the hiring of Tom Winrod and Paula Ulsh. Thomas Winrod, RN, has joined as Associate Director, Clinical Trials Tom has been in healthcare for over 25 years in both patient care and clinical research. Tom comes to CTI from INC Research ...
Read MoreJune 19, 2013
CTI Clinical Trial and Consulting Services (CTI), an international, privately held, full-service contract research organization will present, chair, and exhibit at the DIA 2013 49th Annual Meeting, Advancing Therapeutic Innovation and Regulatory Science, in Boston, June 23-37. CTI’s Ryan Gifford, Senior Manager, will chair the session “Utilizing Electronic Medical ...
Read MoreJune 12, 2013
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of S2 Statistical Solutions (S2). S2, a renowned health outcomes and health economics organization, focuses on the power of analytics through data mining and economic research. S2 specializes in generating and interpreting ...
Read MoreJune 6, 2013
CTI Clinical Trial and Consulting Services (CTI) announces its collaboration with Galectin Therapeutics on a first-in-man Phase I clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH or fatty liver disease) with advanced fibrosis.The Phase 1 Clinical Trial is entitled, "A Multi-Center, Partially ...
Read MoreMay 13, 2013
CTI Clinical Trial and Consulting Services (CTI) announces that is has opened an office in Warsaw, Poland. The office is opened through its newly created wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Poland, sp. z o.o.“Poland, the sixth largest country in Europe, has both a highly educated population and ...
Read MoreMay 1, 2013
Read MoreApril 15, 2013
Timothy J. Schroeder, President and CEO of CTI Clinical Trial and Consulting Services (CTI) will present at Oracle’s 8th Annual Health Sciences Innovation Forum, taking place April 18, 2013 in Parsippany, New Jersey. The forum will explore and discuss the evolving requirements of the health sciences industry.Mr. Schroeder will present ...
Read MoreApril 10, 2013
Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD 02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis. ...
Read MoreMarch 26, 2013
CTI Clinical Trial and Consulting Services (CTI) has joined the Alliance for Regenerative Medicine (ARM), an advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. According to their website, “ARM also works to increase public understanding of the field and ...
Read MoreFebruary 11, 2013
CTI Clinical Trial and Consulting Services (CTI) will be one of the sponsors of the 8th Annual New York Stem Cell Summit, taking place February 19, 2013. The faculty will include more than 30 of the world’s leaders in this industry to lead discussions on investment opportunities, groundbreaking products, and ...
Read MoreFebruary 1, 2013
CTI Clinical Trial and Consulting Services (CTI) announces its expanded capabilities in global drug processing and reporting services with the addition of Oracle® Argus Safety 7.1. Oracle® Argus Safety 7.1 is used to capture and process drug safety information from clinical studies and from drug products in the pre-clinical and ...
Read More